Sugi Predict

Sugi Predict / Compounds / SCHEMBL1783880

SCHEMBL1783880

SCHEMBL1783880

CC(C)(C)OC(=O)NC1C[CH]C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.51
▸ NFKB1 P19838 1/20 0.49
▸ NFKB2 Q00653 1/20 0.49
▸ RELA Q04206 1/20 0.49
▸ EPHX2 P34913 1/20 0.48
▸ CTSK P43235 2/20 0.47
▸ GAA P10253 2/20 0.46
▸ KDM1A O60341 2/20 0.44
▸ MAOB P27338 1/20 0.44
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ EPHX1 P07099 1/20 0.41
▸ CYP2C9 P11712 1/20 0.40
▸ HSD11B1 P28845 1/20 0.40
▸ DRD2 P14416 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458573 0.88 BTK (0.51) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL18498476 0.87 BTK (0.51) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL6458006 0.83 BTK (0.55) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL25223172 0.83 BTK (0.55) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL28611976 0.83 BTK (0.55) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL3702157 0.81 BTK (0.61) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL1406894 0.81 BTK (0.61) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL3702152 0.81 BTK (0.61) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL10343938 0.81 BTK (0.61) BTKNFKB1NFKB2RELAEPHX2
SCHEMBL1498382 0.81 BTK (0.53) BTKNFKB1NFKB2RELAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313951-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-02-07 — — EP disclosed
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 — — EP disclosed
CN-115867319-A Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2023-03-28 — — CN disclosed
US-10227331-B2 Metallo-β-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-12 — — US disclosed
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS Marck Sharp & Dohme Corp. (US) 2018-06-28 — — US disclosed
EP-3337476-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2018-06-27 — — EP disclosed
EP-3157917-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2017-04-26 — — EP disclosed
WO-2017030814-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2017-02-23 — — WO disclosed
WO-2015196071-A9 COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-02-18 — — WO disclosed
WO-2015196071-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-12-23 — — WO disclosed
EP-2820014-A1 HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Amgen Inc. (US) 2015-01-07 — — EP disclosed
WO-2013130890-A1 HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS AMGEN INC. (US) 2013-09-06 — — WO disclosed
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 — — US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 — — EP disclosed
CN-103097384-A Substituted imidazo [1,2-a ] pyrimidines and pyridines BAYER IP GMBH 2013-05-08 — — CN disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 — — US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 — — US disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 — — EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 — — US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R BTK 606/4885NFKB1 2180/4885NFKB2 2327/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R BTK 2211/4885NFKB1 1266/4885NFKB2 996/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R BTK 2325/4885NFKB1 1447/4885NFKB2 341/4885
US-10227331-B2 Metallo-β-lactamase inhibitors ALPI, GAA, ZFX BTK 127/4885NFKB1 1399/4885NFKB2 1924/4885
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS ALPI, GAA, ZFX BTK 135/4885NFKB1 1348/4885NFKB2 1880/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R BTK 606/4885NFKB1 2180/4885NFKB2 2327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.